St. Jude Medical, Inc. recently announced the U.S. launch and the first U.S. implant of its Quadra Assure MP™ cardiac resynchronization therapy defibrillator (CRT-D). The Quadra Assura MP™ features St. Jude Medical’s first-to-market MultiPoint™ Pacing (MPP) technology. The device received CE Mark Approval for MRI Compatibility in December 2015 and the MPP technology received U.S. FDA approval earlier this year. According to the press release, the first implant of the Quadra Assura MP™ took place at Saint Francis Hospital in Hartford, Connecticut.
Heart failure patients frequently experience ventricle contraction or beating that is out of sync. CRT synchronizes the ventricle contraction. According to the press release, the first-to market MPP technologies allow physicians to pace multiple locations on the left side of the patient’s heart. According to the American Heart Association, “heart failure (HF) is a chronic, progressive condition in which the heart muscle is unable to pump enough blood through to meet the body’s needs for blood and oxygen.” The condition affects over 5.8 million in the USA and over 23 million worldwide. Despite the success of CRT, according to a recent study, one third of the HF patients fail to respond to CRT. The same study shows that MPP optimizes the response of such non-responsive patients to CRT. According to St. Jude, MPP is also featured on St. Jude Medical’s Quadra Allure MP™ CRT-pacemaker (CRT-P) and two new Quartet™ Quadripolar LV Leads.
Regarding the first implant, Dr. Mark D. Carlson, Chief Medical Officer and Vice President, Global Clinical Affairs, at St. Jude Medical, stated:
St. Jude Medical developed and established a new standard of care for CRT with quadripolar pacing. We are excited to bring the next-generation MultiPoint Pacing technology to market, giving physicians additional options to improve patient response.
We are now able to offer St. Jude Medical’s new MultiPoint Pacing technology for our patients whose heart failure condition is difficult to manage. It is important for us to have this option to individualize patient care and help improve response to therapy.